GlassScriptPhysician profile
John R Wendt
NPI 1851377816
$9,805.53
in general payments reported to CMS, 2019-2025
42 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,387 · 2020: $572 · 2021: $1,496 · 2022: $1,516 · 2023: $1,943 · 2024: $1,523 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,835.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,488.12 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $1,145.91 | 2019-2025 | |
| Inari Medical, INC. | $1,028.10 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $950.08 | 2019-2024 | Xarelto |
| Abbott Laboratories | $809.64 | 2019-2025 | Mitraclip, Assurity, Quadra Allure Mp |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $564.04 | 2019-2025 | Lifevest |
| Pfizer INC. | $430.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $375.91 | 2019-2025 | Farxiga, Wainua |
| Abiomed | $373.39 | 2021-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $363.71 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $296.42 | 2021-2025 | Verquvo |
| Amgen INC. | $271.85 | 2019-2023 | Repatha |
| Edwards Lifesciences Corporation | $231.00 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.21 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $124.19 | 2021-2025 | Onpattro |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $116.67 | 2021-2025 | Corevalve Evolut R |
| Penumbra, INC. | $97.67 | 2021-2025 | Indigo System, Ruby Coil |
| Cvrx, INC. | $95.52 | 2024 | Barostim Neo System |
| Philips North America LLC | $84.59 | 2020-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Stryker Corporation | $73.35 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Kowa Pharmaceuticals America, INC. | $64.44 | 2020-2021 | |
| Cardiva Medical, INC. | $55.78 | 2022-2025 | Optowire, Savvywire |
| Novo Nordisk INC | $54.62 | 2024 | Wegovy |
| Shockwave Medical, INC | $49.57 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $44.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $44.57 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $34.80 | 2024 | |
| Amarin Pharma, INC. | $34.21 | 2021 | |
| Kestra Medical Technology Services, INC. | $33.57 | 2023 | Assure Wcd |
| Astellas Pharma US INC | $33.54 | 2019 | |
| Esperion Therapeutics, INC. | $32.13 | 2022-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $26.19 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.93 | 2023 | Uptravi, Opsumit |
| Lundbeck LLC | $21.95 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $21.52 | 2023 | Arcalyst |
| Zoll Medical Corporation | $20.04 | 2025 | Defibrillator |
| Kiniksa Pharmaceuticals International, Plc | $18.77 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $18.49 | 2023 | Arexvy, Shingrix |
| Atricure, INC. | $17.68 | 2024 | |
| Convatec INC. | $15.07 | 2021 | |
| Irhythm Technologies, INC. | $14.81 | 2023 | Zio Xt Patch |
| Medtronic Vascular, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wendt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.